1 ML belimumab 200 MG/ML Auto-Injector — RxCUI 1939296
RxNorm drug concept · Semantic clinical drug
RxCUI 1939296
Semantic clinical drug · SCD
● Current RxNorm concept 3 FDA products
7 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1939296
Official name1 ML belimumab 200 MG/ML Auto-Injector
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asbelimumab 200 MG per 1 ML Auto-Injector; belimumab 200 MG in 1 ML Auto-Injector
FDA products mapped3
Package NDCs mapped7
Reported Medicaid activity (SDUD)62,832 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Belimumab Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Benlysta isn't a cure for lupus, but it helps control the disease. It targets an overactive part of your immune system that's driving inflammation and damage. It's used on top of y...
- What exactly is Benlysta treating — is it a cure for lupus?
- That depends on which form you're using. The intravenous (IV) version has to be given at a clinic or infusion center by a healthcare provider. The subcutaneous (under-the-skin) ver...
- Can I give myself the shot at home, or do I have to go to a clinic every time?
🕸️ Concept Web — How 1 ML belimumab 200 MG/ML Auto-Injector Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
1 ML belimumab 200 MG/ML Auto-Injector
RxCUI 1939296 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Belimumab
1092437IN
-
Belimumab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Benlysta
1092441BN
-
Benlysta
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Belimumab Auto-Injector
1939295SCDF -
Belimumab Injectable Product
1159402SCDG -
Belimumab Auto-Injector [Benlysta]
1939298SBDF -
Benlysta Injectable Product
1171464SBDG -
Auto-Injector
1649570DF -
Injectable Product
1151126DFG
-
Belimumab Auto-Injector
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Belimumab 200 MG/ML
1939294SCDC -
1 ML belimumab 200 MG/ML Auto-Injector [Benlysta]
1939299SBD -
Belimumab 200 MG/ML [Benlysta]
1939297SBDC
-
Belimumab 200 MG/ML
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Belimumab 200 MG/ML
SCDC · 1939294 -
Belimumab Auto-Injector
SCDF · 1939295 -
Belimumab Injectable Product
SCDG · 1159402
Brand-Name Concepts
-
1 ML belimumab 200 MG/ML Auto-Injector [Benlysta]
SBD · 1939299 -
Belimumab 200 MG/ML [Benlysta]
SBDC · 1939297 -
Belimumab Auto-Injector [Benlysta]
SBDF · 1939298 -
Benlysta Injectable Product
SBDG · 1171464 -
Benlysta
BN · 1092441
📦 FDA Products & Package NDCs
3 products · 7 package NDCs
7 package NDCs map to RxCUI 1939296 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 49401-0088-02 | 1 SYRINGE in 1 CARTON (49401-088-02) / 1 mL in 1 SYRINGE (4... | BENLYSTA | GlaxoSmithKline LLC | 2017-07-20 |
| 49401-0088-35 | 4 SYRINGE in 1 CARTON (49401-088-35) / 1 mL in 1 SYRINGE (4... | BENLYSTA | GlaxoSmithKline LLC | 2017-07-20 |
| 49401-0088-47 | 4 SYRINGE in 1 CARTON (49401-088-47) / 1 mL in 1 SYRINGE (4... | BENLYSTA | GlaxoSmithKline LLC | 2017-07-20 |
| 49401-0088-50 | 1 SYRINGE in 1 CARTON (49401-088-50) / 1 mL in 1 SYRINGE (4... | BENLYSTA | GlaxoSmithKline LLC | 2017-07-20 |
| 49401-0088-61 | 1 SYRINGE in 1 CARTON (49401-088-61) / 1 mL in 1 SYRINGE | BENLYSTA | GlaxoSmithKline LLC | 2020-06-02 |
| 49401-0101-01 | 1 VIAL in 1 CARTON (49401-101-01) / 1.5 mL in 1 VIAL | BENLYSTA | GlaxoSmithKline LLC | 2011-03-10 |
| 49401-0102-01 | 1 VIAL in 1 CARTON (49401-102-01) / 5 mL in 1 VIAL | BENLYSTA | GlaxoSmithKline LLC | 2011-03-10 |
Observed labelers:
GlaxoSmithKline LLC (7)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J0490 | Belimumab injection | 2 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.